Conclusions
| Home | | Pharmacovigilance |Chapter: Pharmacovigilance: The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Children and Adolescents
This review aimed to address the pressing clinical question of whether SSRI use for the treatment of depression differs in youth than in adults.
CONCLUSIONS
This
review aimed to address the pressing clinical question of whether SSRI use for
the treatment of depression differs in youth than in adults. Both efficacy and
safety data raise serious concerns that youth outcomes are different,
particularly in children. Data have been presented and their findings have been
critiqued. Suggestions for further research are posed. Many publicized
interpretations of the existing stud-ies suggest that the glass is ‘half full’
when the major long-term concern for use of SSRIs to treat depression in youth
warrants a ‘half empty’ interpre-tation. Regardless of the clinical readers’
perspective, wisdom and FDA warnings demand caution and close monitoring.
Related Topics
